Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)

NCT07265947 is registered in ClinicalTrials.gov with Tyra Biosciences, Inc as lead sponsor.

NCT NCT07265947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07265947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)
Lead sponsor
Tyra Biosciences, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
December 22, 2025
Completion date
November 30, 2030
Enrollment
230 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

low grade upper tract urothelial carcinoma